John Libbey Eurotext

Sang Thrombose Vaisseaux

MENU

C-reactive protein and haemostasis: in vivo role and in vitro analytical interferences Volume 34, issue 6, November-December 2022

Authors
1 Université de Tunis El Manar, Faculté de médecine de Tunis, Rue Djebal Lakhdar, 1006 Tunis, Tunisie <mariemcheikhrouhou@gmail.com>
2 Centre hospitalo-universitaire Charles Nicolle, laboratoire d’hématologie et banque du sang, Boulevard du 9 avril 1983, Tunis, Tunisie
* Tirés à part : M. Cheikhrouhou

C-reactive protein (CRP) is a protein whose base levels increase in response to acute or chronic inflammation. It is not only an inflammatory marker but also a well-established risk factor for cardiovascular disease. It is a common actor between inflammation and thrombosis. In vivo, it is present in two distinct isoforms: a plasma form (pentameric CRP or CRPp) and a tissue form (monometric CRP or CRPm). The latter, through its interaction with cellular elements of the inflammatory environment, is actively involved in the pathogenesis of arterial thrombosis in vivo. CRP interference with the haemostatic system extends in vitro. Indeed, by its affinity of binding to phospholipids, CRP can induce false prolongation of clotting times dependent on phospholipids. The degree of lengthening of clotting times depends not only on the plasma CRP levels but also on the reagent-automat couple used. Thus, high levels of CRP in a proven inflammatory context should attract the attention of the biologist to possible analytical interference that he must take into consideration in the biological validation of routine and specialized coagulation tests.